Literature DB >> 2393868

Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

M Lund-Johansen1, R Bjerkvig, P A Humphrey, S H Bigner, D D Bigner, O D Laerum.   

Abstract

Effects of epidermal growth factor (EGF) and an antibody (Ab-528) reactive against the binding site for EGF on human EGF receptors were studied on multicellular tumor spheroids obtained from three human glioma cell lines with high (D-37 MG), medium (D-247 MG), and low (D-263 MG) levels of EGF receptor expression. The D-247 MG and D-263 MG spheroids grew slowly or not at all in the absence of EGF, while in the presence of EGF they were growth stimulated. Tumor cell migration, as measured by the spread of cells from spheroids on a plastic substratum, was increased by the addition of EGF for all three cell lines. Stimulation of migration could be blocked by a subsequent addition of Ab-528 to the medium at a concentration of 50 micrograms/ml. Invasiveness of glioma cell spheroids into fetal rat brain aggregates was related to EGF receptor expression; the two lines with medium to high receptor expression (D-247 MG and D-37 MG) were invasive, while the line with low EGF receptor expression (D-263 MG) was noninvasive, as assessed by an in vitro coculture assay. In the D-247 MG cell line, morphometry revealed EGF-enhanced invasiveness of the tumor cells. The addition of the Ab-528 to EGF-treated cocultures reduced invasion in both D-247 MG and D-37 MG cell lines. Antibody Ab-528 alone did not affect glioma cell growth or migration but did inhibit invasiveness. The present study suggests that, in brain tumors with an increased number of normal-sized Mr 170,000 EGF receptors, EGF or an EGF-like ligand such as transforming growth factor-alpha may selectively facilitate expansive tumor growth and tumor cell invasion. This effect may in part be blocked or retarded by specific antibodies to the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393868

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  86 in total

Review 1.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

2.  Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease.

Authors:  Daniel Paris; Nowel Ganey; Magdalena Banasiak; Vincent Laporte; Nikunj Patel; Myles Mullan; Susan F Murphy; Gi-Taek Yee; Corbin Bachmeier; Christopher Ganey; David Beaulieu-Abdelahad; Venkatarajan S Mathura; Steven Brem; Michael Mullan
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

3.  Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Authors:  Michael R Zalutsky; Abraham Boskovitz; Chien-Tsun Kuan; Charles N Pegram; Joanne Ayriss; Carol J Wikstrand; Anne F Buckley; Eric S Lipp; James E Herndon; Roger E McLendon; Darell D Bigner
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

4.  Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression.

Authors:  M E Berens; M D Rief; J R Shapiro; D Haskett; A Giese; A Joy; S W Coons
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

5.  Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.

Authors:  Toshiyuki Murai; Takayuki Miyauchi; Toshio Yanagida; Yasushi Sako
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

6.  3D Printed Multiplexed Competitive Migration Assays with Spatially Programmable Release Sources.

Authors:  Alexander P Haring; Emily G Thompson; Raymundo D Hernandez; Sahil Laheri; Megan E Harrigan; Taylor Lear; Harald Sontheimer; Blake N Johnson
Journal:  Adv Biosyst       Date:  2019-12-05

7.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

8.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

9.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Authors:  Paul D Brown; Sunil Krishnan; Jann N Sarkaria; Wenting Wu; Kurt A Jaeckle; Joon H Uhm; Francois J Geoffroy; Robert Arusell; Gaspar Kitange; Robert B Jenkins; John W Kugler; Roscoe F Morton; Kendrith M Rowland; Paul Mischel; William H Yong; Bernd W Scheithauer; David Schiff; Caterina Giannini; Jan C Buckner
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 10.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.